Wellgistics Health

What Wellgistics Health does

Wellgistics Health, Inc. is a Delaware-incorporated, publicly traded (NASDAQ: WGRX) healthcare technology and pharmaceutical logistics company headquartered in Tampa, Florida. The company operates a vertically integrated platform connecting 200+ pharmaceutical manufacturers with 6,500+ independent pharmacies across all 50 U.S. states, providing NABP-accredited wholesale distribution, 3PL cold chain logistics, backend pharmacy services with 48-state licenses, and direct-to-consumer mail fulfillment. Its stated mission is to simplify prescription fulfillment from manufacturer to patient by combining a proprietary tech stack with an alternative distribution channel that bypasses pharmacy benefit managers.

The platform is built on two AI-driven products, EinsteinRx and HubRx AI, which perform intelligent prescription routing, prior authorization automation, eligibility and benefits verification, and auto-application of manufacturer copay cards. These are paired with PharmacyChain, a blockchain-enabled smart contract platform for manufacturer-to-patient tracking and dispensing, developed under a multi-phase partnership with Datavault AI and integrating quantum key encryption and tokenization. Recent product additions include Forzet, a proprietary medical food addressing muscle loss associated with GLP-1 therapies, and PBM-free distribution of TheracosBio's Brenzavvy (bexagliflozin), positioned below typical insurance copays.

Wellgistics earns revenue through wholesale pharmaceutical distribution, 3PL cold chain logistics fees, AI hub services for pharmacy partners (EinsteinRx/HubRx), PharmacyChain SaaS with potential usage-based revenue sharing, proprietary medical food product sales, Medicare-reimbursable chronic care and remote patient monitoring services, and transaction-related fees on its Capital Access Program with RxERP Financial. The company is publicly listed as a micro-cap (approximately $34 million market capitalization in early 2026), executed a 1-for-50 reverse stock split in May 2026 to maintain Nasdaq compliance, and is pursuing an aggressive growth strategy centered on the planned DelivMeds AI joint venture (expected combined asset value of approximately $4 billion) and two LOI-stage acquisitions (Neuritek Therapeutics and WellCare Today).

Name

Wellgistics Health

Legal name

Wellgistics Health, Inc.

Website

https://wellgisticshealth.com

Company type

Public

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Wellgistics Health is a publicly traded (NASDAQ: WGRX) healthcare technology and pharmaceutical logistics company operating an NABP-accredited distribution and AI/blockchain-enabled pharmacy platform connecting 200+ manufacturers with 6,500+ independent pharmacies across all 50 U.S. states.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution & Healthcare Technology

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmacies and Drug Retailers (456110)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Health & Pharmacy Omnichannel (CRAFAEAK)

akta.pro secondary industries

Pharmacy & Health Essentials Delivery (CRAFAFAI), Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG)

Keywords

• Pharmaceutical distribution
• Prescription fulfillment logistics
• Healthcare technology platform
• Pharmacy benefit management
• Specialty pharmaceutical services

Headquarters

HQ city

Lakeland

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Wholesale Pharmaceutical Distribution: Core revenue stream from distributing prescription drugs via the NABP-accredited wholesale distributor and 3PL cold chain operations to 6,500+ independent pharmacies across all 50 states
2. PharmacyChain SaaS / Smart Contracts: SaaS-based blockchain-enabled tracking and dispensing platform with potential revenue-sharing model based on usage fees with DataVault AI
3. HubRx AI / EinsteinRx Hub Services: AI-powered pharmacy hub services including prescription routing, prior authorization workflows, eligibility and benefits verification, and manufacturer copay card auto-application for pharmacy partners
4. Medical Food Product Sales (Forzet, Tollovid): Distribution of proprietary medical foods targeting GLP-1 muscle loss and Long COVID through affiliated pharmacy and 6,500+ pharmacy network, with plans for direct-to-consumer telehealth expansion
5. Remote Patient Monitoring / Chronic Care Management Services: Medicare-reimbursable RPM, RTM, and CCM services through MSO pilot with Kare Clinicals and proposed WellCare Today acquisition integrating Samsung Galaxy Watch-enabled RPM
6. Capital Access Program Financing: Partnership with RxERP Financial offering financing up to $350,000 per independent pharmacy and up to $1M per wholesaler/manufacturer integrated directly into the Wellgistics/RxERP store platform

Pricing tiers

Go-to-market motion5 records

Distribution channels6 records

Marketing channels7 records

Core offering

Wellgistics Health is a healthcare technology and pharmaceutical logistics company that operates a vertically integrated prescription ecosystem combining an NABP-accredited wholesale distribution and 3PL cold-chain network, blockchain-enabled PharmacyChain tracking, AI-powered EinsteinRx and HubRx AI prescription management hubs, and a nationwide network of 6,500+ independent pharmacies serving 200+ manufacturers. It simplifies prescription fulfillment from manufacturer to patient via a PBM-free maker-to-taker platform, with emerging direct-to-patient online pharmacy, telehealth, and medical food offerings.

Product overview

Wellgistics Health operates a vertically integrated healthcare technology and pharmaceutical logistics platform composed of a core blockchain-enabled prescription ecosystem (PharmacyChain (TM)), AI prescription management hubs (EinsteinRx (TM) and HubRx AI (TM)), and a nationwide distribution and pharmacy fulfillment network spanning 6,500+ independent pharmacies, 200+ manufacturers, and 48-state pharmacy licenses. The platform layers on add-on modules such as the Wellgistics Patient App for adherence, a Capital Access Program with RxERP Financial, the planned Health Lives Here consumer app, and the new $4B DelivMeds AI joint venture combining HaaS IP, QOLPOM biometric verification, AI-enabled drone logistics, and a controlling stake in Tollo Health's medical food portfolio (Forzet (TM)). Product offerings include Forzet (TM) medical food for GLP-1 muscle loss, PBM-free Brenzavvy (R) diabetes drug distribution, and forthcoming drone-based medical logistics, all supported by Datavault AI's blockchain IDE and quantum key encryption, a partnership with NFL Alumni Health for consumer outreach, and an MSO pilot with Kare PharmTech/Kare Clinicals for chronic care management and remote patient monitoring.

Differentiator

Problem solved

Functional benefit

Brands

• PharmacyChain(TM): Blockchain-enabled manufacturer-to-patient smart contract tracking and dispensing platform for the prescription drug industry, developed in partnership with DataVault AI; integrating quantum key encryption and tokenization capabilities.
• EinsteinRx(TM)
• HubRx AI(TM)
• Forzet(TM)
• Health Lives Here
• Wellgistics Pharmacy
• Wellgistics Hub
• Wellgistics Distribution

Products and services

• PharmacyChain Blockchain-enabled smart contract platform for manufacturer-to-patient prescription drug tracking and dispensing; integrates Datavault AI's Information Data Exchange (IDE), quantum key encryption, Insurance Eligibility & Benefits Verification (EBV), and tokenization of AI-enabled pharmacy operations across the 6,500+ pharmacy network.
• EinsteinRx AI prescription management hub that connects pharmacies, physicians, and manufacturers to optimize drug delivery, pricing, and patient adherence while supporting smart contract execution for pharmacy services and EBV integration.
• HubRx AI AI platform for intelligent and efficient routing of prescriptions with auto-application of manufacturer copay cards for eligible patients; powers pharmacy operations across the 6,500+ independent pharmacy network.
• Brenzavvy Distribution PBM-free distribution of FDA-approved Brenzavvy (bexagliflozin), an SGLT-2 inhibitor for Type 2 diabetes, across 6,500+ independent pharmacies using the maker-to-taker platform that bypasses pharmacy benefit managers.
• Forzet Medical Food Proprietary medical food formulation for the dietary management of muscle loss associated with GLP-1 agonist therapies (Ozempic, Wegovy, Mounjaro); distributed via the affiliated pharmacy and 6,500+ pharmacy network with EinsteinRx AI point-of-sale recommendations.
• Wellgistics Pharmacy Network Nationwide network of 6,500+ locally owned independent pharmacies providing direct-to-consumer mail order pharmacy, backend pharmacy services, prior authorization assistance, copay/discount cards, clinical concierge services, and 48-state pharmacy licenses; NABP accredited in all 50 states.
• Wellgistics Wholesale Distribution & 3PL Wholesale pharmaceutical distribution plus 3PL and cold chain logistics for 200+ manufacturers; NABP accredited in all 50 states; supports the company's maker-to-taker platform that bypasses PBMs.
• Wellgistics 3PL Cold Chain Third-party logistics services including cold chain distribution for pharmaceutical manufacturers; supports wholesale distribution with NABP accreditation across all 50 states.
• TolloCare Telehealth Platform White-labeled telemedicine platform with 5,000+ onboarded physicians integrated into Wellgistics' patient services offering for GLP-1, Long COVID, cardiometabolic, sleep apnea, pain management, and mental health patients.

Quantifiable outcome

• Q1 2026 pharmacy revenue grew from $0.1M to $0.6M (6x year-over-year)
• +5 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability15 records

Feature7 records

Partnerships

Twelve partnerships are on record, tiered flagship, core and minor.

• EOS Technology Holdings and Scilex Holding CompanyflagshipOEM/ Whitelabel/ Licensing Partner · 20 May 2026Acquisition of the QOLPOM patent portfolio from EOS Technology Holdings and Scilex Holding Company for biometric patient verification and AI-enabled drone delivery IP. This IP is being contributed to the DelivMeds AI transaction with Datavault AI, Wellgistics Health, and HealthBridge Advisors, with expected combined asset value of approximately $4 billion.
• HealthBridge AdvisorscoreStrategic or Co-development Partner · 20 May 2026Co-participant in the DelivMeds AI Transaction alongside Datavault AI, EOS Technology Holdings, and Scilex Holding Company. Wellgistics Health is contributing DelivMeds AI Transaction parties including its pharmacy network and Tollo Health stake, with expected combined asset value of approximately $4 billion subject to independent fairness opinion.
• WellCare Today, LLCcoreStrategic or Co-development Partner · 14 May 2026Non-binding letter of intent to acquire WellCare Today for approximately $15 million ($3M cash plus performance-based earnout in preferred stock). WellCare Today operates a remote health monitoring platform integrated with Samsung Galaxy Watch devices providing Medicare-reimbursable RPM, RTM, and CCM programs. Would integrate with Wellgistics' MSO pilot involving Kare Clinicals.
• Kare PharmTech and Kare ClinicalscoreStrategic or Co-development Partner · 13 May 2026Pilot MSO collaboration supporting chronic care management (CCM) and remote patient monitoring (RPM) services across multiple provider offices. Leverages Wellgistics' 6,500+ independent pharmacy network to identify eligible patients. Pilot has generated 1,500+ claims. Targets $14 billion U.S. RPM market (projected ~$29 billion by 2030, 12.6% CAGR).
• KareRx HubcoreStrategic or Co-development Partner · 14 April 2026Definitive joint venture agreement combining pharmaceutical technology platforms and operations. Integrates Wellgistics' EinsteinRx and HubRx AI with KareRx's digital hub infrastructure for prescription routing, prior authorization workflows, and direct-to-patient fulfillment. Combined ecosystem targets access to 200,000+ patient lives.
• Neuritek Therapeutics, Inc.coreStrategic or Co-development Partner · 23 March 2026Non-binding Letter of Intent to evaluate a potential $105 million all-stock acquisition of Neuritek Therapeutics, a neuroscience-focused research organization pioneering innovative therapies for neurological and psychiatric disorders. Aims to expand Wellgistics' healthcare platform by adding research capabilities adjacent to its pharmacy distribution business. Transaction subject to due diligence and board approval.
• San Francisco Mental Health AI Startup (stealth)coreStrategic or Co-development Partner · 18 February 2026Strategic investment in a stealth San Francisco Bay Area mental health AI startup on the cusp of launching its service following successful beta testing. Strengthens Wellgistics' expanded partnership with Tollo Health and supports patient engagement for prescription drug compliance, particularly for GLP-1 patients. Targets the $6.3 billion (2025) mental health software market projected to reach $18.1 billion by 2033.
• Tollo Health (TolloCare subsidiary)coreStrategic or Co-development Partner · 11 February 2026Expanded partnership adding telehealth, mental health AI, and public health information through TolloCare (Tollo Health subsidiary). TolloCare integrates telemedicine with 5,000+ onboarded physicians and partners with a stealth San Francisco mental health AI startup. Wellgistics gains controlling stake in Tollo Health via DelivMeds AI; products include Forzet and Tollovid targeting GLP-1 patients and Long COVID sufferers.
• NFL Alumni HealthflagshipGTM or Marketing Partner · 9 February 2026Strategic partnership to deploy AI-powered pharmacy technology (EinsteinRx) and blockchain smart contracts (PharmacyChain) to improve healthcare outcomes for former NFL players and underserved rural communities. Programs focus on mental health, weight loss, sleep apnea, cardiometabolic disease, pain management, and Long COVID, with NFL Alumni Health Ambassadors supporting outreach. Partnership publicly highlighted during Super Bowl LX in San Francisco.
• Peek Healthcare Technologies, Inc.minorStrategic or Co-development Partner · 22 November 2025Originally announced on April 10, 2025, Wellgistics entered into a definitive agreement to acquire Peek Healthcare Technologies, a digital healthcare platform specializing in prescription shopping and consulting. Acquisition was subsequently terminated in November 2025 as it no longer aligned with the company's strategic plans.
• Datavault AI (formerly WiSA Technologies)flagshipStrategic or Co-development Partner · 27 October 2025Multi-phase strategic partnership encompassing SaaS agreement for PharmacyChain development (Oct 2025), patents licensing for digital ledger-enabled smart contracts (Nov 2025), quantum key encryption integration (Jan 2026), Healthcare-as-a-Service expansion (Feb 2026), and binding term sheet to form DelivMeds AI with combined expected asset value of approximately $4 billion (May 2026). Wellgistics distributes through its 6,500+ pharmacy network; DataVault contributes smart contract patents, IDE platform, and AI/data monetization capabilities.
• TheracosBiocoreChannel Partner/ Reseller/ Distributor · 30 September 2025Strategic collaboration to expand nationwide, PBM-free access to Brenzavvy (bexagliflozin), an FDA-approved SGLT-2 inhibitor for type 2 diabetes, through Wellgistics' network of 6,500+ independent and chain pharmacies. Uses Wellgistics' 'maker-to-taker' platform to bypass PBMs and reduce costs below typical insurance copays. Rollout began Q4 2025.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• TRxADE Health: Pharmaceutical technology platform serving independent pharmacies with secondary distribution, reverse distribution, and logistics; founded by Wellgistics' Chairman Suren Ajjarapu and Co-CEO Prashant Patel. Direct predecessor and closest analog in distribution-to-independents plus pharma IT model.
• GoodRx: Direct-to-consumer prescription drug pricing transparency and telehealth platform operating a marketplace model. Comparable to Wellgistics' Health Lives Here consumer app, Brenzavvy under-copay positioning, and PBM-bypass narrative targeting affordability-conscious consumers.

Broad incumbents

• McKesson Corporation: Largest U.S. pharmaceutical wholesaler and distributor with nationwide infrastructure serving retail, institutional, and manufacturer customers. Represents the incumbent scale and contract advantages Wellgistics' wholesale and 3PL operations must compete against.
• Cencora (formerly AmerisourceBergen): One of the 'Big 3' U.S. pharmaceutical distributors with global wholesale, specialty distribution, and consulting operations. Directly comparable to Wellgistics' wholesale, 3PL, and specialty distribution franchises, but at vastly greater scale.
• Cardinal Health: Major U.S. pharmaceutical distributor and medical products company operating a national wholesale network and at-Home Solutions business. Directly comparable wholesale footprint against which Wellgistics' maker-to-taker model must win manufacturer contracts.
• CVS Health (incl. CVS Caremark): Integrated retail pharmacy, PBM (Caremark), and health services conglomerate that is simultaneously target and counterparty for PBM reform; comparable to Wellgistics' pharmacy network and PBM-free positioning.
• Walgreens Boots Alliance: Major U.S. retail pharmacy chain and drug distribution platform competing for independent pharmacy partnerships and consumer prescriptions; relevant incumbent comparable for Wellgistics' pharmacy network economics.

Emerging players

• Hims & Hers Health: Direct-to-consumer telehealth and online pharmacy company selling prescription treatments (including GLP-1 weight loss) with no retail footprint. Comparable to Wellgistics' planned direct-to-patient online pharmacy, telehealth integration via TolloCare, and GLP-1-adjacent Forzet medical food.
• Alto Pharmacy: Tech-enabled digital pharmacy offering free same-day delivery, in-app refills, and price transparency. Comparable direct-to-consumer pharmacy playbook against which Wellgistics' direct-to-patient pivot and 48-state pharmacy licenses will compete.

Others

• DataVault AI (formerly WiSA Technologies): Data monetization and blockchain/AI infrastructure company licensing smart contract patents and quantum key encryption to Wellgistics and forming the DelivMeds AI joint venture. Closely adjacent enabling technology partner with significant strategic and economic overlap via the $4B combined asset transaction.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/wellgistics
• Facebookfacebook.com/wellgistics
• LinkedInlinkedin.com/company/wellgistics
• Instagraminstagram.com/wellgisticshealth

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries6 records

Funding overview

Funding rounds6 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wellgistics Health